Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US

被引：0
|
作者：
William V. Padula
Sonal Parasrampuria
Mariana P. Socal
Rena M. Conti
Gerard F. Anderson
机构：
[1] University of Southern California,Department of Pharmaceutical and Health Economics, School of Pharmacy, USC Schaeffer Center
[2] University of Southern California,Leonard D. Schaeffer Center for Health Policy and Economics
[3] Johns Hopkins Bloomberg School of Public Health,Department of Health Policy and Management
[4] Boston University Questrom School of Business,Institute for Health System Innovation and Policy
来源：
PharmacoEconomics | 2020年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1115 / 1121
页数：6
相关论文
共 50 条
  • [41] Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
    Dhodapkar, Meera
    Zhang, Audrey D.
    Puthumana, Jeremy
    Downing, Nicholas S.
    Shah, Nilay D.
    Ross, Joseph S.
    JAMA NETWORK OPEN, 2021, 4 (06)
  • [42] ALEMTUZUMAB BUDGET IMPACT ANALYSIS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE US
    Celestin, C.
    Wandstrat, T.
    Coleman, C., I
    VALUE IN HEALTH, 2015, 18 (03) : A280 - A280
  • [43] BUDGET IMPACT ANALYSIS WITH SIMULTANEOUS MULTIPLE MARKET ENTRANTS: STATIC VERSUS DYNAMIC BASELINE MARKET SHARES
    O'Day, K.
    Meyer, K.
    VALUE IN HEALTH, 2018, 21 : S10 - S10
  • [44] Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
    Aniek Dane
    Anne-Sophie Klein Gebbink
    Jan-Dietert Brugma
    Albane Degrassat-Théas
    Martin J. Hug
    Morten B. Houlind
    P. Paubel
    P. Hugo M. van der Kuy
    Carin A. Uyl-de Groot
    Applied Health Economics and Health Policy, 2023, 21 : 905 - 914
  • [45] Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
    Dane, Aniek
    Gebbink, Anne-Sophie Klein
    Brugma, Jan-Dietert
    Degrassat-Theas, Albane
    Hug, Martin J.
    Houlind, Morten B.
    Paubel, P.
    van der Kuy, P. Hugo M.
    Uyl-de Groot, Carin A.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2023, 21 (06) : 905 - 914
  • [46] Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches
    Broder, Michael S.
    Zambrano, Jenelle M.
    Lee, Jackie
    Marken, Richard S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (05) : 765 - 773
  • [47] US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
    Dolph, Mike
    Tremblay, Gabriel
    Leong, Hoyee
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 493 - 502
  • [48] An empirical analysis of changes of the impact of federal budget deficits on stock market returns: evidence from the US economy
    Grobys, Klaus
    APPLIED ECONOMICS LETTERS, 2013, 20 (09) : 921 - 924
  • [49] EVALUATING THE ADHERENCE TO ISPOR GUIDELINES IN US PUBLISHED BUDGET IMPACT ANALYSES OF NEW DRUGS: A TARGETED LITERATURE REVIEW
    Amaefule, A. Q.
    Thakkar, K.
    Erb, R. S.
    Rascati, K. L.
    VALUE IN HEALTH, 2023, 26 (06) : S399 - S399
  • [50] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Ghanem, Buthainah
    Shi, Lu
    CLINICAL DRUG INVESTIGATION, 2022, 42 (12) : 1085 - 1092
12345